PF 5105679Alternative Names: PF-05105679
Latest Information Update: 16 Mar 2016
At a glance
- Originator Pfizer
- Class Analgesics
- Mechanism of Action TRPM8 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 30 Sep 2011 Pfizer completes a phase I trial in Healthy volunteers in Belgium (NCT01393652)
- 23 May 2011 Phase-I clinical trials in Pain in Belgium (unspecified route)